A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
Table 4
Subgroup and metaregression analysis of ORR and DCR.
Subgroups
No. of studies
ORR
DCR
OR (95% CI)
I2
Heterogeneity value
value
MM value
UM value
OR (95% CI)
I2
Heterogeneity value
value
MM value
UM value
Subgroup and metaregression analysis according to study type (Figures S10–S11)
CCS
6
3.91 (2.32, 6.59)
0%
0.76
<0.001
0.277
0.104
2.38 (1.37, 4.11)
4%
0.39
0.002
0.043
0.945
RCT
7
3.79 (1.82, 7.88)
62%
0.01
<0.001
3.64 (2.25, 5.89)
15%
0.24
<0.001
Subgroup and metaregression analysis according to study sample size (Figures S12–S13)
<50
6
5.54 (2.54, 12.12)
46%
0.10
<0.001
0.123
0.029
3.45 (1.96, 6.07)
12%
0.34
<0.001
0.018
0.030
≥50
7
2.56 (1.69, 3.87)
0%
0.43
<0.001
2.78 (1.74, 4.44)
27%
0.22
<0.001
Subgroup and metaregression analysis according to treatment process (Figures S14–S15)
FSMC
5
6.00 (2.31, 15.58)
55%
0.07
<0.001
0.810
0.123
3.75 (2.19, 6.42)
19%
0.29
<0.001
0.284
0.107
FPC
6
2.98 (1.77, 5.02)
23%
0.26
<0.001
2.99 (1.59, 5.62)
14%
0.33
<0.001
FFC
1
2.38 (0.88, 6.47)
—
—
0.09
2.80 (1.13, 6.96)
—
—
0.03
Unclear
1
1.88 (0.39, 9.01)
—
—
0.43
0.72 (0.15, 3.54)
—
—
0.69
Subgroup and metaregression analysis according to dosage of apatinib (Figures S16–S17)
250 mg
2
3.42 (1.51, 1.76)
46%
0.18
0.003
0.477
0.910
1.90 (0.85, 4.24)
48%
0.16
0.12
0.446
0.713
425 mg
1
1.37 (0.56, 3.38)
—
—
0.49
4.14 (1.04, 16.44)
—
—
0.04
500 mg
8
4.10 (2.10, 8.00)
40%
0.11
<0.001
3.08 (1.98, 4.81)
28%
0.22
<0.001
Unclear
2
5.03 (2.11, 12.00)
0%
0.34
<0.001
7.03 (1.51, 32.70)
0%
0.82
0.01
Subgroup and metaregression analysis according to chemotherapy regimen (Figures S18–S19)
Platinum
2
3.89 (1.52, 9.92)
0%
0.75
0.004
0.852
0.696
4.85 (1.94, 12.16)
0%
0.86
<0.001
0.435
0.456
Taxanes or anthracycline
6
4.98 (2.22, 11.19)
58%
0.04
<0.001
2.64 (1.52, 4.59)
43%
0.13
<0.001
Taxanes + platinum
2
1.48 (0.68, 3.24)
0%
0.73
0.32
2.03 (0.76, 5.43)
62%
0.10
0.16
Gemcitabine
2
2.76 (1.26, 6.03)
0%
0.64
0.01
3.02 (1.46, 6.25)
0%
0.79
0.003
Taxanes + anthracycline
1
8.22 (2.16, 31.27)
—
—
0.002
8.27 (0.97, 70.73)
—
—
0.05
Subgroup and metaregression analysis according to chemotherapy cycle (Figures S20–S21)
<4
2
1.76 (0.90, 3.43)
0%
0.42
0.10
0.290
0.472
3.18 (1.49, 6.78)
0%
0.64
0.003
0.334
0.294
4–6
4
4.82 (2.67, 8.69)
0%
0.91
<0.001
3.84 (1.75, 8.45)
0%
0.89
<0.001
>6
1
8.22 (2.16, 31.27)
—
—
0.002
8.27 (0.97, 70.73)
—
—
0.05
Unclear
6
3.81 (1.62, 8.98)
55%
0.05
0.002
2.49 (1.52, 4.10)
51%
0.07
<0.001
Note: ORR: objective response rate, DCR: disease control rate, CI: confidence interval, UM: univariate metaregression, MM: multiple metaregression, CCS: case-control study, RCT: randomized clinical trial, FFC: failure of first-line chemotherapy, FPC: failure of platinum chemotherapy, and FSMC: failure of second- or multiple-line chemotherapy.
